Mingzhen Yang

Hefei, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest.

Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest.

Journal: Frontiers in oncology

Published: February 12, 2026

Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.

Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.

Journal: Cancer cell international

Published: October 28, 2025

CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments.

CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments.

Journal: Clinical and experimental medicine

Published: June 05, 2025

Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.

Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.

Journal: Oncogene

Published: February 23, 2025

Low-dose ATG/PTCy for graft-versus-host disease prevention in haploidentical transplantation: a single-center experience.

Low-dose ATG/PTCy for graft-versus-host disease prevention in haploidentical transplantation: a single-center experience.

Journal: Frontiers in oncology

Published: January 31, 2025

Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.

Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.

Journal: Cancer cell international

Published: November 01, 2024

SFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia.

SFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia.

Journal: Cell biochemistry and biophysics

Published: May 17, 2024

Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin-resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation.

Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin-resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation.

Journal: Research and practice in thrombosis and haemostasis

Published: April 04, 2024

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.

Journal: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica

Published: February 23, 2024

Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns.

Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns.

Journal: Scientific reports

Published: February 20, 2024

Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders.

Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders.

Journal: Clinics (Sao Paulo, Brazil)

Published: December 20, 2023

Knowledge, attitude, and practice toward leukemia in the general population and among family members of patients with leukemia: A cross-sectional study.

Knowledge, attitude, and practice toward leukemia in the general population and among family members of patients with leukemia: A cross-sectional study.

Journal: Heliyon

Published: September 25, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026